WM (WM) Q3 2025 Earnings Call Transcript

Waste Management reported third-quarter operating EBITDA growth of more than 15% and free cash flow growth of nearly 33%, with total company operating EBITDA margin reaching a record 30.6%. Management raised full-year margin guidance to 29.6%-30.2% and reiterated strong 2026 free cash flow potential of about $3.8 billion, supported by lower sustainability capex and better legacy business economics. Revenue guidance was trimmed to the low end of prior ranges due to weaker recycled commodity prices and softer-than-expected Healthcare Solutions revenue, but synergy capture, cross-selling, and cost discipline remain strong.

Analysis

WM is quietly transitioning from a “price discipline” story into a cash-recapture story. The important second-order effect is that several prior drags are rolling off simultaneously: fleet refresh, sustainability buildout, and healthcare integration all move from absorption of capital to monetization of sunk investment, which should mechanically expand free cash flow faster than EBITDA in 2026. That matters because the market often underestimates how much earnings quality improves when capex intensity normalizes; this is not just incremental margin, it is a denominator reset in FCF conversion.

The biggest hidden lever is Healthcare Solutions. Near-term noise from credits and delayed price realization is masking what is likely a multi-quarter normalization in pricing once billing/ERP stabilization completes by early 2026. The key insight is that the business does not need heroic revenue growth to matter: if churn stays contained and the company converts more of the installed base into single-provider relationships, the segment can become a source of cross-sell gravity for the legacy waste network while also reducing SG&A intensity. That creates a compounding effect that should show up first in retained accounts, then in higher wallet share, and only later in reported top-line acceleration.

On the sustainability side, the market is likely over-focusing on commodity weakness and underappreciating operating leverage from automation. The recycling and RNG businesses are increasingly shaped by self-help, not spot pricing: lower labor intensity, better contract structures, and more presold output reduce earnings volatility even when commodity baskets remain soft. The temporary idling of Natura PCR is a signal that flexible plastics remain an uneconomic market absent regulation or brand-owner willingness to pay; that is bearish for standalone PCR economics but bullish for WM’s discipline, because it prevents capital from being wasted in structurally flawed end-markets.

Net: this is a higher-quality compounder than the headline revenue guide implies, but the near-term setup is still better on pullbacks than on strength. The next catalyst is not just the Q4 print; it is the 2026 capital-allocation framework, where buybacks could become a meaningful increment on top of already durable dividend growth. The main risk is that healthcare stabilization slips beyond 1Q26 or recycled commodity prices stay depressed longer than expected, which would delay the cash inflection and keep the stock in a defensive multiple box.

Key Decisions for Investors

• Long WM on 3-6 month horizon into 2026 guidance reset; thesis is FCF inflection and buyback capacity. Risk/reward improves on any selloff tied to commodity weakness or healthcare noise.
• Use a bullish call spread in WM (e.g., 6-9 month tenor, near-the-money / +10% strike) to express upside from 2026 FCF re-rating while limiting downside if Healthcare Solutions stabilization slips.
• Pair trade: long WM / short a basket of more commodity-sensitive recycling or waste adjacencies over 1-2 quarters. WM’s operating leverage and pricing power should outperform peers exposed to spot commodity spreads.
• If WM sells off on another quarter of healthcare revenue volatility, add rather than exit; the risk is timing, not thesis, and the stabilization period appears bounded to early 2026.
• Watch for a catalyst trade around Q1 2026 results: if healthcare pricing normalizes and FCF cadence confirms the ~$3.8B run-rate, scale into equity ahead of likely capital return announcements.